Distinguishing DLBCL

Genomics-based subtyping could improve prognostic predictions for DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens.

Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of patients do not respond to the standard combination chemotherapy consisting of Rituxan rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Read the full 526 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE